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Background: Interleukin (IL)1a and IL1b, and their endogen-
ous receptor antagonist (IL1Ra), have been related to the
pathology of systemic lupus erythematosus (SLE), but the role
of IL1 polymorphisms in the aetiology of SLE is unknown.
Objective: To examine polymorphisms at IL1a 2889(CRT),
IL1a +4845(CRT), IL1b 2511(CRT), IL1b +3953(GRT),
and IL1Ra (86 bp VNTR) in a population based study of SLE
in North Carolina and South Carolina.
Methods: Genotypes from 230 cases who met ACR classi-
fication criteria, and from 275 controls matched for age, sex,
and state, were analysed separately for African Americans
and whites. Odds ratios (ORs) were estimated by logistic
regression models for each locus alone and also after
adjusting for polymorphisms at adjacent loci.
Results: An increased risk of SLE for the IL1a 2889C/C
genotype compared with carriage of the 2889T allele was
found in both African Americans (OR = 3.1, p = 0.001) and
whites (OR = 2.9, p = 0.005). In African Americans, carriage
of the IL1b 2511T allele was associated with a higher risk of
SLE than carriage of the 2511C/C genotype (OR = 2.4,
p = 0.017), independent of variation at IL1a 2889.
Conclusions: The observed associations support the hypoth-
esis that genetic variation in IL1 is involved in the aetiology of
SLE and merit further investigation.
I
nterleukin (IL)1a and IL1b are proinflammatory cytokines
with widespread biological activities, regulated in part by
the IL1 receptor antagonist (IL1Ra). Differences in IL1 and
IL1Ra production have been seen in systemic lupus erythe-
matosus (SLE).1 2 The IL1 gene cluster (IL1a, IL1b, IL1Ra) is
located on a 430 kb region of chromosome 2 (2q13-21).
Polymorphisms include biallelic single nucleotide poly-
morphisms in IL1a at position 2889(CRT)3 and in exon 5
at +4845(GRT),4 and in IL1b at position 2511(CRT)5 and in
exon 5 at +3953(CRT).6 Data on allelic variation at these sites
in patients with SLE are limited. One study reported that
polymorphisms in IL1b (2511 and +3953) were not
associated with SLE.7 Variation in the penta-allelic 86 base
pair tandem repeat (VNTR) in intron 2 of IL1Ra,8 specifically
the uncommon allele (IL1Ra allele 2), has been inconsistently
linked to SLE susceptibility.9 10
The Carolina Lupus Study is a population based case-
control study conducted in the southeastern United States.
We examined five polymorphic loci in the IL1 gene cluster
(IL1a 2889, IL1a +4845, IL1b 2511, IL1b +3953, and the
IL1RA 86 base pair VNTR region) with respect to SLE,
and estimated the effects of these polymorphisms on




Patients with SLE (diagnosed between January 1995 and July
1999, meeting the 1997 revised American College of
Rheumatology (ACR) classification criteria) in 60 counties
of North Carolina and South Carolina were referred through
30 community based rheumatologists and four university
rheumatology practices. Controls matched for sex and state,
identified through state driver’s licence records for the 60
study counties, were randomly selected and frequency
matched to cases in five-year age groups. Study protocols
were approved by the institutional review boards of the
National Institute of Environmental Health Sciences and
other participating institutions. Details on sample enrolment
have been presented previously.11 The final sample consisted
of 265 cases and 355 controls. Ninety per cent of cases were
female, 60% were African American, and the mean age at
diagnosis was 39 years (range 15–81). Thirty per cent of
controls were African American, reflecting the racial dis-
tribution of the study area.
Genotyping
Blood specimens were used to obtain DNA from 243 (92%)
cases and 298 (84%) controls. DNA specimens were
genotyped for IL1a 2889(CRT), IL1a +4845(CRT), IL1b
2511(CRT), and IL1b +3953(GRT) biallelic restriction
fragment length polymorphisms.326 Specimens were ampli-
fied using polymerase chain reaction and digested with
restriction enzymes Fun4H1, Nco1, AvaI, and a Taq, res-
pectively. IL1Ra 86 bp VNTR genotypes were determined by
polymerase chain reaction based methods.8 Alleles were
differentiated by visual determination of size relative to
known markers (allele 1 = 4 repeats, allele 2 = 2 repeats,
allele 3 = 5 repeats, and allele 4 = 3 repeats).
Analyses
Genotypes from 230 cases (144 African-American, 86 white)
and 275 controls (73 African-American, 202 white) were
examined in parallel analyses for African Americans and
whites. Linkage disequilibrium was examined using the
estimating haplotypes program (http://linkage.rockefeller.
edu/ott/eh.html) (a= 0.05). We used the x2 statistic (Fisher’s
exact test for cell size ,5) to compare genotype frequency in
cases and controls at each locus. Odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated by unconditional
logistic regression. We did not adjust for multiple compar-
isons. Models were run for each locus separately, comparing
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Abbreviations: CI, confidence interval; IL, interleukin; IL1Ra, interleukin
1 receptor antagonist; OR, odds ratio; SLE, systemic lupus
erythematosus; VNTR, variation in tandem repeat
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the genotypes containing the variant allele with the homo-
zygous wild-type genotype. Independent associations at each
locus also were estimated in a model containing all five loci
to adjust for potential confounding by linkage disequili-
brium. Only the main effects at each locus were examined,
except for the interaction of the two promoter polymorph-
isms (IL1a 2889 and IL1b 2511) with respect to SLE and
proteinuria in African Americans. Proteinuria was defined as
two or more urine samples containing >3 mg/ml albumin
reported in medical records up to six months after diagnosis.
RESULTS
Table 1 shows the frequency of IL1a, IL1b, and IL1Ra
genotypes in patients with SLE and controls. Genotype
frequencies were determined to be in Hardy-Weinberg
equilibrium, and were significantly different (p,0.05) in
African-American and white controls at all loci except IL1a
2889. Genotype frequencies at IL1a 2889 differed between
cases and controls in both African Americans and whites: the
IL1a 2889C/T genotype was inversely associated with SLE
compared with the IL1a 2889C/C genotype in single locus
models (African Americans OR = 0.4, p = 0.004; whites
OR = 0.5, p = 0.006). Carriage of the IL1a 2889T allele was
inversely associated with SLE in the five locus model (African
Americans OR = 0.3, p = 0.001; whites OR = 0.3, p = 0.005).
Viewed as a positive risk factor, the IL1a 2889C/C genotype
was associated with a threefold increased risk of SLE in both
African Americans (OR = 3.1; 95% CI 1.5 to 6.1, p = 0.001)
and whites (OR = 2.9; 95% CI 1.4 to 6.0, p = 0.005) compared
with carriage of the IL1a 2889T allele. We observed no
significant effect for number of copies of IL1a 2889T. The
IL1a +4845 polymorphism was not significantly associated
with SLE.
In single locus models, the IL1b 2511C/T genotype was
significantly associated with SLE in African Americans
(OR = 2.5, p = 0.016) compared with the C/C genotype, and
carriage of the IL1b 2511T allele was associated with SLE
(OR = 2.4, p = 0.017) in the five locus model. We observed no
significant effect for number of copies of the IL1b 2511T
allele in African Americans, and no association in whites. The
IL1b +3953 polymorphism was not significantly associated
with SLE.
Allelic variation at IL1Ra was significantly associated with
SLE in African Americans (exact p = 0.01), driven in part by
Table 1 Frequencies of IL1a, IL1b, and IL1Ra genotypes and associations with SLE*
African Americans Whites
Cases (n = 144) Controls (n = 73) Cases (n = 86) Controls (n = 202)
Genotypes n (%) n (%) OR (95% CI) n (%) n (%) OR (95% CI)
IL1a 2889
C/C 62 (43) 18 (25) 1.0 (referent) 43 (50) 68 (34) 1.0 (referent)
C/T 57 (40) 43 (59) 0.4 (0.2 to 0.7) 32 (37) 109 (54) 0.5 (0.3 to 0.8)
T/T 25 (17) 12 (16) 0.6 (0.3 to 1.4) 11 (13) 25 (12) 0.7 (0.3 to 1.6)
x2 (2df)` 8.4, p = 0.015 7.6, p = 0.022
C/T or T/T v C/C (single locus model) 0.4 (0.2 to 0.8) 0.5 (0.3 to 0.8)
C/T or T/T v C/C (five locus model) 0.3 (0.2 to 0.7) 0.3 (0.2 to 0.7)
IL1a +4845
G/G 96 (67) 54 (74) 1.0 (referent) 45 (52) 95 (47) 1.0 (referent)
G/T 39 (27) 18 (25) 1.2 (0.6 to 2.4) 27 (31) 83 (41) 0.7 (0.4 to 1.2)
T/T 8 (6) 1 (1) – 14 (16) 24 (12) 1.2 (0.6 to 2.6)
x2 (2df) 2.5, p = 0.28 2.1, p = 0.26
G/T or T/T v G/G (single locus model) 1.4 (0.7 to 2.6) 0.8 (0.5 to 1.3)
G/T or T/T v G/G (five locus model) 1.8 (0.9 to 3.5) 1.3 (0.6 to 2.7)
IL1b 2511
C/C 23 (16) 21 (29) 1.0 (referent) 41 (48) 89 (44) 1.0 (referent)
C/T 73 (51) 27 (37) 2.5 (1.2 to 3.8) 36 (42) 87 (43) 0.9 (0.5 to 1.5)
T/T 48 (33) 25 (34) 1.8 (0.8 to 3.8) 9 (10) 26 (13) 0.8 (0.3 to 1.7)
x2 (2df) 5.9, p = 0.052 0.48, p = 0.79
C/T or T/T v C/C (single locus model) 2.1 (1.1 to 4.2) 0.9 (0.5 to 1.4)
C/T or T/T v C/C (five locus model) 2.4 (1.2 to 4.9) 0.8 (0.4 to 1.3)
IL1b +3953
C/C 111 (77) 61 (85) 1.0 (referent) 49 (57) 121 (60) 1.0 (referent)
C/T 32 (22) 10 (14) 1.8 (0.8 to 3.8) 31 (36) 67 (33) 1.1 (0.7 to 2.0)
T/T 1 (1) 1 (1) – 6 (7) 13 (6) 1.1 (0.4 to 3.2)
x2 (2df) 2.3, p = 0.31 0.26, p = 0.88
C/T or T/T v C/C (single locus model) 1.6 (0.8 to 3.5) 1.1 (0.7 to 1.9)
C/T or T/T v C/C (five locus model) 1.6 (0.7 to 3.5) 1.6 (0.8 to 3.0)
IL1Ra VNTR
1/1 130 (90) 63 (87) 1.0 (referent) 63 (73) 160 (79) 1.0 (referent)
1/2 6 (4) 3 (4) 1.0 (0.2 to 4.0) 12 (14) 18 (9) 1.7 (0.8 to 3.7)
2/2 1 (1) 0 (0) – 8 (9) 15 (7) 1.4 (0.6 to 3.4)
1/3 1 (1) 6 (8) – 3 (3) 7 (3) 1.1 (0.3 to 4.3)
3/3 0 (0) 0 (0) – 0 (0) 2 (1) –
1/4 6 (4) 0 (0) – 0 (0) 0 (0) –
x2 (4df) 12.2, p = 0.016 2.9, p = 0.58
1/2 or 2/2 v other genotypes (single locus model) 1.2 (0.3 to 4.7) 1.6 (0.8 to 3.0)
1/2 or 2/2 v other genotypes (five locus model) 0.8 (0.2 to 3.2) 1.7 (0.9 to 3.4)
*Frequencies based on total number shown except as follows. In African Americans: IL1a +4845 based on 143 patients and IL1b +3953 based on 72 controls. In
whites: IL1b +3953 based on 201 controls; OR (odds ratios) and 95% CI (confidence intervals) were derived from logistic regression models comparing the
homozygous wild-type genotype with other genotypes. Values are derived from single locus models except where shown for the five locus models. Odds ratios and
confidence intervals are not presented for genotypes with fewer than three cases or controls; `x2 statistic shown. Fisher’s exact statistic also calculated for IL1Ra
(p = 0.01 in African Americans and p = 0.61 in whites), and for IL1a +4845 (p = 0.33) and IL1b +3953 (p = 0.28) in African Americans.
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carriage of IL1Ra allele 3, which was significantly less
common in African-American cases than in controls (exact
p = 0.006) and inversely associated with SLE (OR = 0.1, 95%
CI 0.0 to 0.7). Variation at IL1Ra was not significantly
associated with SLE in whites, though IL1Ra allele 2 was
more common in patients with SLE than controls (OR = 1.7,
p = 0.102).
Table 2 shows the frequency of estimated haplotypes. There
was little evidence of linkage disequilibrium among the five
loci in African Americans except between IL1a 2889 and
+4845 in both cases and controls (controls, p,0.005; cases,
p,0.0001). In whites, there was significant linkage disequi-
librium for most pairwise comparisons.
None of the genotypes were independently associated with
proteinuria, although IL1Ra allele 2 was non-significantly
raised in white cases with proteinuria (25% v 9%; OR = 3.3,
p = 0.077). In African Americans no interaction was seen
between IL1a 2889 and IL1b 2511 genotypes for overall risk
of SLE (p = 0.938), but a highly significant interaction
(p = 0.002) was seen for risk of proteinuria. Paradoxically,
the combined IL1a 2889 C/C, IL1b 2511T genotype was
positively associated with risk of SLE (OR = 2.4, 95% CI 1.2 to
5.1; p = 0.019), but inversely associated with proteinuria
(OR = 0.4, 95% CI 0.2 to 0.9; p = 0.027).
DISCUSSION
As far as we know this is the first study to simultaneously
examine these five loci with respect to SLE and to report an
association between allelic variation at IL1a 2889 and SLE.
In both African-Americans and whites, the IL1a 2889C/C
genotype was associated with a threefold higher risk of SLE
than carriage of the T allele. The IL1a 2889C/C genotype has
been associated with other inflammatory and autoimmune
diseases, including scleroderma.12 In African Americans,
carriage of the IL1b 2511T allele was also associated with
increased risk of SLE, even after adjusting for variation at
IL1a 2889. A previous study in China reported no association
between this locus and SLE.7 We did not observe a dose effect
for the number of copies of the IL1a 2889T or IL1b 2511T
alleles. However, repeating this study with a larger sample
size would provide greater power to detect such a relation-
ship.
These two IL1 promoter polymorphisms may affect IL1
production. The IL1a 2889C/C genotype has been associated
with significantly lower transcriptional activity of the IL1a
gene and lower levels of IL1a in plasma compared with the
T/T genotype.13 Variation in IL1a may also affect the
production of IL1b: in healthy Finnish subjects, plasma
IL1b was lower in those with IL1a 2889C/C than in those
with the T/T genotype.14 The IL1b 2511 polymorphism, linked
to the IL1b 231 TATA box polymorphism that affects DNA-
protein interactions in vitro,15 may reflect potential for altered
levels of gene expression. There has been little indication of
an effect of IL1b 2511, however, on IL1b levels in vivo.14
Our results do not support the hypothesis that IL1Ra allele
2 affects the risk of SLE. However, our ability to detect an
association might be limited by the low frequency of this
allele in our study group, especially among African
Americans. The inconsistent findings for this locus might
also be due to differences in linkage disequilibrium with
other relevant loci in the IL1 gene cluster.9 10 IL1Ra allele 2
has been associated with increased production of IL1Ra and
IL1b, and decreased production of IL1a,16 suggesting that
these genes should be studied collectively.
We considered these analyses to be useful for generating a
hypothesis and did not adjust for multiple comparisons.
However, a post hoc analysis yielded a highly significant
(p,0.0001) overall association between IL1a 2889C/C and
SLE that remained significant (p,0.0005) after Boneferroni
adjustment. Our confidence in the association between the
IL1a 2889C/C genotype and SLE is increased by the similar
magnitude of effect in African-Americans and whites despite
different racial patterns of linkage disequilibrium across the
IL1 gene cluster. Population based sampling of controls can
help to minimise the effects of selection bias and population
stratification. The proportion of African-American controls in
this sample reflected the racial distribution in the study area
based on census estimates, resulting in fewer African-
American controls than white controls or African-American
cases. None the less, the observed associations in African
Americans were statistically significant.
In conclusion, polymorphisms in two IL1 gene promoter
regions were significantly associated with SLE in this study
sample. Variation at both loci may affect IL1 and IL1Ra
production, supporting the hypothesis that altered or
imbalanced IL1 production may affect the risk of developing
SLE.
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Table 2 Frequency of estimated haplotypes including five polymorphic loci within the





2889 +4845 2511 +3953 VNTR Cases Controls Cases Controls
C G T C 1 32 27 16 19
C G C C 1 20 24 30 28
C G C T 1 0 0 5 1
C G T C 2 1 1 8 4
T G T C 1 12 13 2 2
T T C T 1 3 0 15 16
T G C C 1 8 12 2 5
T G T T 1 2 5 0 0
T T C C 1 5 6 6 6
*Estimated haplotypes shown if carried by at least 5% of participants in either white or African-American cases or
controls.
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